EUVIMEDDécouvrir EUVIMED
Open access · CC BY 4.0

Comparison of software vs. cognitive‐based fusion‐targeted biopsies for prostate cancer diagnosis

Marcus Westerberg iD, Rolf Gedeborg, Hans Garmo, Fredrik Jäderling, Pär Stattin, David Robinson iD

BJUI Compass · 2026-07 · 7 (7)

DOI: 10.1002/bco2.70248 ↗

At a glance

Journal article in BJUI Compass, published online on 2026-07-12. Written by Marcus Westerberg and 5 co-authors. Institution: Department of Surgical Sciences Uppsala University Uppsala Sweden. 21 references. The full text is freely available (open access, CC BY 4.0). Funded by: Vetenskapsrådet, Cancerfonden, Forskningsrådet om Hälsa, Arbetsliv och Välfärd.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Objectives

This study aimed to compare the effectiveness of software‐based fusion‐targeted biopsies (STBx) versus cognitive fusion‐targeted biopsies (CogTBx) in detecting prostate cancer (PCa) and clinically significant PCa. Materials and methods Men aged 30–85 were included in a target trial emulation if they had undergone a STBx or CogTBx of Prostate Imaging Reporting and Data System (PI‐RADS) 3–5 lesions in 2020–2024. Using log‐link binary regression models with inverse probability of treatment weighting to adjust for confounding, we estimated the associations between biopsy technique and detection of PCa and clinically significant PCa (Gleason ≥3 + 4 and Gleason ≥4 + 3) by use of adjusted relative risks (aRR) with 95% confidence intervals (CIs) obtained via bootstrapping.

Results

A total of 2092 men who underwent STBx and 7933 men who underwent CogTBx in 2020–2024 were identified in PCBase Xtend. The overall proportion diagnosed with PCa was 64%. STBx detected PCa with a slightly higher frequency (aRR, 1.05; 95% CI, 1.02–1.09), corresponding to an absolute increase of 3.3 percentage points (95% CI 1.2–5.3). The relative risk for detection of Gleason ≥4 + 3 was somewhat larger (aRR, 1.13; 95% CI, 1.03–1.23). The largest relative difference for detection of PCa was observed in PI‐RADS 3 lesions (aRR, 1.12; 95% CI, 1.01–1.24), and this pattern became even more apparent when the outcome was restricted to clinically significant PCa.

Conclusions

Software‐based fusion‐targeted biopsies detected slightly more PCa and clinically significant PCa compared to cognitive fusion‐targeted biopsies, particularly in men with PI‐RADS 3 lesions. Prioritizing PI‐RADS 3 lesions for software‐based targeted fusion biopsy could optimize diagnostic effectiveness.

Subjects

Author keywords

cognitive‐based fusion biopsymagnetic resonance imagingprostate cancersoftware‐based fusion biopsytargeted biopsy

Authors and institutions

  • Department of Surgical Sciences Uppsala University Uppsala Sweden.
  • Department of Molecular Medicine and Surgery (MMK) Karolinska Institutet Stockholm Sweden.
  • Department of Radiology Capio S:t Görans Hospital Stockholm Sweden.
  • Department of Urology Skåne University Hospital Malmö Sweden.
  • Department of Urology Höglandssjukhuset Eksjö Sweden.

ORCID profiles: Marcus Westerberg, David Robinson

Funding

  • Vetenskapsrådet
  • Cancerfonden
  • Forskningsrådet om Hälsa, Arbetsliv och Välfärd
  • Akademiska Sjukhuset
  • Futurum - Akademin för Hälsa och Vård, Region Jönköpings läns
  • Allmänna Sjukhusets i Malmö Stiftelse för Bekämpande av Cancer

Cite

APA

Westerberg, M., Gedeborg, R., Garmo, H., Jäderling, F., Stattin, P., & Robinson, D. (2026). Comparison of software vs. cognitive‐based fusion‐targeted biopsies for prostate cancer diagnosis. BJUI Compass, 7(7). https://doi.org/10.1002/bco2.70248

Vancouver

Westerberg M, Gedeborg R, Garmo H, Jäderling F, Stattin P, Robinson D. Comparison of software vs. cognitive‐based fusion‐targeted biopsies for prostate cancer diagnosis. BJUI Compass. 2026;7(7). doi:10.1002/bco2.70248

BibTeX
@article{Westerberg2026,
  author = {Westerberg, Marcus and Gedeborg, Rolf and Garmo, Hans and Jäderling, Fredrik and Stattin, Pär and Robinson, David},
  title = {Comparison of software vs. cognitive‐based fusion‐targeted biopsies for prostate cancer diagnosis},
  journal = {BJUI Compass},
  year = {2026},
  volume = {7},
  number = {7},
  doi = {10.1002/bco2.70248}
}
Start for free →